A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Under this condition, which can result from traumatic injuries, infections, metabolic problems, or could be inherited due to ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Henry Ford Health System in Detroit recently provided the first patient in Michigan — a 60-year-old man from the Cadillac ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence rev ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...